July 22, 2025 02:00 ET | Source: Scancell Holdings Plc SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent…
“It was an outstanding quarter. We exceeded our Q1 projections with approximately 34% YOY growth from our first two verticals,…